Pacira BioSciences, Inc.
General ticker "PCRX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.1B (TTM average)
Pacira BioSciences, Inc. follows the US Stock Market performance with the rate: 4.1%.
Estimated limits based on current volatility of 1.7%: low 23.71$, high 24.52$
Factors to consider:
- Total employees count: 790 (+11.0%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Strategic risks and growth management, Product development risks, Market competition
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.74$, 25.30$]
- 2025-12-31 to 2026-12-31 estimated range: [11.73$, 23.40$]
Financial Metrics affecting the PCRX estimates:
- Positive: with PPE of 6.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: Operating cash flow per share per price, % of 21.23 > 13.24
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.86 <= 3.41
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Positive: 41.86 < Shareholder equity ratio, % of 50.10 <= 63.39
Short-term PCRX quotes
Long-term PCRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $655.92MM | $674.98MM | $700.97MM |
| Operating Expenses | $595.90MM | $587.30MM | $774.34MM |
| Operating Income | $60.02MM | $87.67MM | $-73.37MM |
| Non-Operating Income | $-46.72MM | $-25.97MM | $10.27MM |
| Interest Expense | $39.98MM | $17.31MM | $16.57MM |
| R&D Expense | $84.80MM | $76.26MM | $81.58MM |
| Income(Loss) | $13.30MM | $61.70MM | $-63.11MM |
| Taxes | $-2.61MM | $19.75MM | $36.45MM |
| Profit(Loss)* | $15.91MM | $41.95MM | $-99.56MM |
| Stockholders Equity | $775.01MM | $870.13MM | $778.35MM |
| Inventory | $96.06MM | $104.35MM | $125.28MM |
| Assets | $1,681.20MM | $1,574.39MM | $1,553.52MM |
| Operating Cash Flow | $145.27MM | $154.65MM | $189.39MM |
| Capital expenditure | $30.08MM | $15.16MM | $10.64MM |
| Investing Cash Flow | $-225.19MM | $77.54MM | $-83.28MM |
| Financing Cash Flow | $-401.53MM | $-183.03MM | $17.36MM |
| Earnings Per Share** | $0.35 | $0.91 | $-2.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.